Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

May 2023; 10 (3) Diagnostic & Treatment ChallengesOpen Access

Relapsing Encephalomyelitis After COVID-19 Infection and Vaccination

From the National MS Society Case Conference Proceedings

Shuvro Roy, View ORCID ProfilePaula Barreras, View ORCID ProfileCarlos A. Pardo, Jennifer S. Graves, Scott S. Zamvil, Scott D. Newsome
First published April 4, 2023, DOI: https://doi.org/10.1212/NXI.0000000000200112
Shuvro Roy
From the Department of Neurology (S.R., P.B., C.A.P., S.D.N.), Johns Hopkins School of Medicine; Department of Neurology (J.S.G.), University of California San Diego School of Medicine; and Department of Neurology (S.S.Z.), University of California San Francisco School of Medicine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula Barreras
From the Department of Neurology (S.R., P.B., C.A.P., S.D.N.), Johns Hopkins School of Medicine; Department of Neurology (J.S.G.), University of California San Diego School of Medicine; and Department of Neurology (S.S.Z.), University of California San Francisco School of Medicine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paula Barreras
Carlos A. Pardo
From the Department of Neurology (S.R., P.B., C.A.P., S.D.N.), Johns Hopkins School of Medicine; Department of Neurology (J.S.G.), University of California San Diego School of Medicine; and Department of Neurology (S.S.Z.), University of California San Francisco School of Medicine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlos A. Pardo
Jennifer S. Graves
From the Department of Neurology (S.R., P.B., C.A.P., S.D.N.), Johns Hopkins School of Medicine; Department of Neurology (J.S.G.), University of California San Diego School of Medicine; and Department of Neurology (S.S.Z.), University of California San Francisco School of Medicine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott S. Zamvil
From the Department of Neurology (S.R., P.B., C.A.P., S.D.N.), Johns Hopkins School of Medicine; Department of Neurology (J.S.G.), University of California San Diego School of Medicine; and Department of Neurology (S.S.Z.), University of California San Francisco School of Medicine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott D. Newsome
From the Department of Neurology (S.R., P.B., C.A.P., S.D.N.), Johns Hopkins School of Medicine; Department of Neurology (J.S.G.), University of California San Diego School of Medicine; and Department of Neurology (S.S.Z.), University of California San Francisco School of Medicine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Relapsing Encephalomyelitis After COVID-19 Infection and Vaccination
From the National MS Society Case Conference Proceedings
Shuvro Roy, Paula Barreras, Carlos A. Pardo, Jennifer S. Graves, Scott S. Zamvil, Scott D. Newsome
Neurol Neuroimmunol Neuroinflamm May 2023, 10 (3) e200112; DOI: 10.1212/NXI.0000000000200112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
183

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Prior case studies suggest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vaccines may unmask CNS neuroinflammatory conditions. We present a case of relapsing steroid-responsive encephalomyelitis after SARS-CoV-2 infection and subsequent COVID-19 vaccination. We also characterize the frequency of CNS neuroinflammatory events reported in the literature after both SARS-CoV-2 infection and COVID-19 vaccination.

Glossary

AGNA=
antiglial nuclear antibody;
ANNA=
antineuronal nuclear antibody;
CLIPPERS=
chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids;
COVID-19=
coronavirus disease 2019;
MOGAD=
myelin oligodendrocyte glycoprotein antibody–associated disease;
NMOSD=
neuromyelitis optica spectrum disorders;
PCA=
Purkinje cell cytoplasmic antibody;
SARS-CoV-2=
severe acute respiratory syndrome coronavirus 2

Case Presentation

A 47-year-old man with a history of psoriasis and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection presented with 3 months of subacute lower extremity weakness, erectile dysfunction, and gait instability with falls. His symptoms started 2 weeks after receiving the second of his 2-shot primary mRNA vaccine series for coronavirus disease 2019 (COVID-19) vaccination, which he received 3 months after a mild case of COVID-19. He had no other relevant medical or family history and no recent travel. After evaluation by a urologist, he was prescribed a course of cefdinir for presumed prostatitis. His weakness and gait dysfunction worsened over the ensuing 3 months despite this treatment and prompted his presentation to our hospital.

On initial examination, his vital signs and general medical examination were normal. Neurologic examination demonstrated upbeat nystagmus on vertical gaze. On motor exam, he had increased tone in right lower extremity, 4/5 strength with right knee extension, 4/5 strength with bilateral ankle dorsiflexion and plantar flexion. Reflex testing showed lower extremity hyperreflexia with extensor plantar responses. On sensory exam, he had moderately impaired vibration at the ankles, with positive Romberg test with eye closure but no sensory level. Coordination testing revealed right-sided dysmetria with finger to nose. He had an unsteady gait and only able to walk a few steps without assistance, with complete inability to perform tandem gait.

MRI of the brain and complete spine (Figure 1) demonstrated diffuse innumerable punctate enhancing lesions involving the subcortical white matter, basal ganglia, thalami, brainstem, cerebellum, and the entire spinal cord parenchyma extending to the conus medullaris. There were no obvious T2 hyperintense, T1 hypointense, or fluid-attenuated inversion recovery hyperintense lesions in the brain. There were patchy short tau inversion recovery changes throughout the spinal cord following the same distribution as the enhancing lesions.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Pretreatment MRI Demonstrating Multifocal Enhancing Lesions

(A) Contrast-enhanced brain MRI demonstrating punctate enhancing lesions scattered throughout the brain parenchyma including the subcortical white matter, basal ganglia, cerebellum, and brainstem. (B) Highlighted in the yellow ovals are the prominent areas of punctate, perivascular appearing enhancement throughout the spinal cord.

Serologic workup revealed negative testing for anti-aquaporin-4 immunoglobulin G (AQP4-IgG), myelin oligodendrocyte glycoprotein (MOG)-IgG, paraneoplastic panel (Mayo Clinic Laboratories, which included amphiphysin, antiglial nuclear [AGNA-1], antineuronal nuclear [ANNA-1, ANNA-2, and ANNA-3], collapsin response mediator protein 5 [CRMP5] neuronal voltage-gated potassium channel, P/Q-type calcium channel, and Purkinje cell cytoplasmic [PCA-Tr, PCA-1, and PCA-2] antibodies), rheumatologic markers, and infections.

CSF testing revealed a lymphocytic pleocytosis (10 cells/μL, 88% lymphocytes), mildly elevated protein (61 mg/dL), and matched oligoclonal bands in the CSF and serum. Flow cytometry and cytology, along with the CSF autoimmune myelopathy panel (Mayo Clinic Laboratories, which included amphiphysin, AGNA-1, ANNA-1, ANNA-2, ANNA-3, CRMP-5, dipeptidyl-peptidase-like protein-6, glutamic acid decarboxylase 65, glial fibrillary acidic protein, metabotropic glutamate receptor 1 protein, neuronal intermediate filament, AQP4-IgG, PCA-Tr, PCA-1, and PCA-2) were negative. CSF was also tested for infectious etiologies, including West Nile virus, herpes simplex virus, cytomegalovirus, syphilis, Epstein-Barr virus, Lyme, and nextgeneration sequencing metagenomic studies, all of which were negative. In addition, CSF cytokine profiling was unrevealing without elevation of interleukin 6 or tumor necrosis factor-α. CSF SARS-CoV-2 antibody testing was not available at the time.

Additional diagnostic imaging including a full-body fluorodeoxyglucose-PET with CT scan and scrotal ultrasound did not reveal systemic disease or malignancy. Ocular coherence tomography demonstrated no evidence of optic neuropathy.

Differential Diagnosis

This patient presented with a subacute encephalomyelitis that involved the brain parenchyma, brainstem, cerebellum, and full length of the spinal cord. The differential diagnosis for such a clinicoradiologic syndrome is broad, including infections such as Lyme disease or tuberculosis, neoplasm including lymphoma, or glioma. Immune-mediated causes include neuromyelitis optica spectrum disorders (NMOSD), myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), rheumatologic conditions (e.g., Behcet disease and Sjogren syndrome), neurosarcoidosis, Bickerstaff encephalitis, vasculitic syndromes, and paraneoplastic disease. Of these, neurosarcoidosis, Bickerstaff encephalitis, neuro-Behcet, and paraneoplastic brainstem encephalitis are conditions that particularly target the brainstem.1 The overall pattern of radiologic involvement, temporal course of symptoms, and workup ruled out most of the aforementioned conditions. Notably, certain conditions such as smoldering lymphomas or lymphomatoid granulomatosis can demonstrate an initial presentation of encephalomyelitis, and these are often only confirmed by biopsy, which was not performed in this patient.

Final Diagnosis and Treatment

The patient was diagnosed with immune-mediated encephalomyelitis. The primary cause was felt to be immune-mediated given the relapsing nature of the condition, steroid responsiveness, and absence of other identifiable causes to date, in addition to objective findings of inflammation, including the enhancing MRI lesions, and pleocytosis on CSF testing.

The patient was treated with 5 days of high-dose IV methylprednisolone (1,000 mg), with drastic improvement in gait, strength, and fatigue. He was subsequently discharged on a course of oral prednisone at 80 mg daily and slowly tapered down over several weeks. Two weeks later, his neurologic examination demonstrated near resolution of his neurologic deficits, and repeat MRI of the brain and complete spinal cord also demonstrated resolution of the enhancement.

Over the course of the next 2 months, his oral prednisone was further tapered to 20 mg, at which point he noted worsening symptoms, with examination findings of horizontal and vertical nystagmus, bilateral hip flexion weakness (4/5), a T12 sensory level, and right-sided ataxia. These clinical features prompted treatment with an additional course of IV methylprednisolone (1 g daily for 5 days) and an increase of his daily oral prednisone dose back to 60 mg. A brain and spine MRI was obtained after completing his IV steroid treatment; no obvious enhancement was seen. Unfortunately, as his oral steroids were again tapered to 20 mg, he endorsed worsening symptoms and was admitted to the hospital for evaluation of suspected relapse. Repeat MRI demonstrated recurrent enhancement within the same lesion distribution as his initial presentation and persistent longitudinally extensive hyperintensities within the lateral columns of his spinal cord (Figure 2). A repeat CSF analysis again demonstrated a pleocytosis of 11 cells/μL with 99% lymphocytic predominance, but studies including SARS-CoV-2 antibodies were otherwise unrevealing in the CSF, including cytology and flow cytometry. He was treated again with 5 days of high-dose IV methylprednisolone, with partial improvement although incomplete resolution of his symptoms and deficits.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 MRI After Steroid Taper Demonstrating Recurrence of Multifocal Enhancing Lesions

(A) Contrast-enhanced brain MRI after weaning of oral steroids and recurrence of symptoms, demonstrating punctate enhancing lesions in many of the same areas as seen on initial presentation. (B) Highlighted in the yellow ovals are residual areas of punctate, perivascular enhancement, notably in the same regions as when the patient first obtained imaging.

Given his diagnosis of immune-mediated relapsing encephalomyelitis, he was started on mycophenolate mofetil (now on 1,000 mg twice a day) with overlapping slow tapering of his oral steroids (a few months). He has remained relapse-free on this treatment regimen. Although, he is experiencing increasing spasticity with impaired ambulation which is requiring antispasticity medication and rehabilitation interventions.

Discussion

We report here a rare case of relapsing encephalomyelitis occurring after SARS-CoV-2 infection and subsequent COVID-19 vaccination. The unique radiologic and clinical findings of our patient could fit with a neuroinflammatory and vasculopathic condition such as the syndrome known as chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). CLIPPERS is a T cell–mediated disorder characterized by widespread punctate perivascular inflammation that is exquisitely responsive to steroid treatment.2 On MRI it appears to pepper the pons, but can also involve the supratentorial parenchyma and spinal cord via perivascular inflammation. It can also be associated with an allergic trigger, with several cases demonstrating persistently elevated serum IgE levels.3 Our patient also demonstrated multiple relapses as his corticosteroids were weaned to 20 mg daily, and multiple reports also observed no relapses when chronic corticosteroid dosages were maintained above 20 mg daily.4

However, there has been an absence of laboratory biomarkers to recognize CLIPPERS as a specific disease entity, and given the variability in presentation, multiple alternative conditions may mimic the radiologic and clinical findings. Notably, even the latest proposed diagnostic criteria for CLIPPERS, can be fraught with misdiagnoses. A subsequent case series applying these criteria found a misdiagnosis rate of 31% (13/42 cases), with the most common misdiagnosis being CNS lymphoma, followed by primary CNS angiitis.6 This raises the question of whether CLIPPERS is indeed a true isolated disease as opposed to a syndrome with overlap across multiple conditions. As such, without a biomarker to confirm a diagnosis, one must carefully exclude these other conditions before diagnosing CLIPPERS and be vigilant in monitoring for conditions that may cause such a clinicoradiologic appearance over time.

Apart from respiratory symptoms, SARS-CoV-2 infection can be associated with a variety of classic autoimmune neurologic manifestations, involving either the central or peripheral nervous system. A literature review identified 173 additional cases of CNS neuroinflammatory disease after either SARS-CoV-2 infection or vaccination, with 65 cases of transverse myelitis, 30 cases of optic neuritis, and 78 cases of encephalomyelitis (Table).7,-,15 Most of these cases occurred within 2–3 weeks of either the infection or vaccination as with our patient, although the vast majority of cases in the literature (>70% of each phenotype) occurred in association with infection. Transverse myelitis and encephalomyelitis tended to occur closer to the time of vaccination or infection. Some cases of encephalomyelitis occurred as late as 1 month from the time of COVID-19 or vaccinations, and the ages of patients were primarily distributed in 2 groups, with 20 of 59 patients under age 16 years and 30 of 59 patients being 40 years or older. On average, optic neuritis tended to occur later than transverse myelitis and encephalomyelitis. Notably, among the cases associated with vaccination, 60% (26/43) occurred in the setting of a positive MOG or AQP4 antibody, and these patients were eventually diagnosed with unmasking of MOGAD or NMOSD. Regardless of the type of demyelinating event, all events were far more likely (73% of transverse myelitis, 77% of optic neuritis, and 74% of encephalomyelitis) to occur in association with SARS-CoV-2 infection in comparison to vaccination.7,-,18 Our case was unusual in the degree of brain and spinal cord involvement, particularly the perivascular distribution of the inflammation, as well as the insidious degree of inflammation, with symptoms progressing over several months. Vascular complications and endothelial dysfunction have become increasingly identified in COVID-19, possibly mediated by SARS-CoV-2 targeting angiotensin-converting enzyme 2 receptors that are expressed in multiple organs, including the brain, although the exact pathogenesis remains unknown.19

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

Cases of CNS Neuroinflammatory Conditions After Either SARS-CoV-2 Infection or Vaccination

Our patient's steroid dependency and relapsing course suggest an unmasking of an underlying CNS neuroinflammatory condition, rather than due to direct SARS-CoV-2 CNS infection or a vaccine-related adverse event. Similar courses have been identified with post–SARS-CoV-2 infection or COVID-19 vaccination demyelinating events in patients who were eventually identified to have MS, MOGAD, and NMOSD.20 The initial neuroimaging observations of multifocality and innumerable punctate enhancement in the pons, cerebellum, and spinal cord may suggest a vasculocentric neuroinflammatory process triggered either by systemic immune reactions to SARS-CoV2 epitopes or overactivation of inflammatory responses in a genetically susceptible subject. Similar cases posit that the blood-brain barrier breakdown secondary to endothelial inflammation could facilitate antibodies to initiate and sustain the disease process, with subsequent epitope spreading leading to a relapsing course.21 This hypothesis could be supported by the temporary nature of the patient's matched oligoclonal bands on his initial CSF testing. Despite unrevealing biomarkers for a specific disease entity, the recurrent nature of his relapses with weaning of his steroid treatment necessitated a steroid-sparing agent. We ultimately chose mycophenolate mofetil because it can treat a broad spectrum of neuroinflammatory diseases.

Temporal associations of neurologic conditions with vaccinations and/or infections do not prove causality despite previous reports of such sequelae. Vaccines containing SARS-CoV-2 antigens may enhance autoimmunity by mechanisms including polyclonal activation, epitope spreading, or molecular mimicry in susceptible individuals.22 Our case highlights that the resulting inflammation may be insidious and extensive, though treatable. A literature search of post–COVID-19 vaccination-related CNS complications, as reported in the Vaccine Adverse Event Reporting System, found a total of 185 cases of either transverse myelitis or optic neuritis in association with the Pfizer, Moderna, and Janssen vaccines, underscoring its relative rarity, especially in comparison to approximately 5.2 billion total vaccine doses given by these manufacturers in that time frame (August 27, 2021).23 Alvarez et al.24 published a global report of confirmed postvaccination optic neuritis from December 2020 to June 2021 and identified a total of 55 cases, finding no difference in severity or clinical outcomes by the type of vaccine, although most cases (38/55) were associated with the AstraZeneca vaccine. Other studies have posited that there may be an association between the AstraZeneca vaccine and neurologic autoimmunity, possibly attributable to the viral vector of this vaccine, although it must be noted that these studies did not demonstrate an increase in the incidence of such events after the roll out of the mass vaccination program.16,-,18 Weighing the results of our findings and those in the literature, as COVID-19 constitutes a life-threatening infection in some patients, we feel that the benefits of vaccination outweigh the extremely rare event of unmasking an immune-related condition or leading to another neuroinflammatory event.

Our case represents a rare case of relapsing encephalomyelitis with the appearance of vasculocentric appearance or CLIPPERS-like radiologic findings after a one-two-punch of SARS-CoV-2 infection followed by COVID-19 vaccination. Prompt treatment of these conditions and understanding when patients may require long-term immune therapy may help prevent accrual of neurologic disability.

Study Funding

The authors report no targeted funding.

Disclosure

The authors report no relevant disclosures. Go to Neurology.org/NN for full disclosures.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the National MS Society.

  • Submitted and externally peer reviewed. The handling editor was Editor Josep O. Dalmau, MD, PhD, FAAN.

  • COVID-19 Resources: NPub.org/COVID19

  • Received December 10, 2022.
  • Accepted in final form February 9, 2023.
  • Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Jubelt B,
    2. Mihai C,
    3. Li TM,
    4. Veerapaneni P
    . Rhombencephalitis/brainstem encephalitis. Curr Neurol Neurosci Rep. 2011;11(6):543-552.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Taieb G,
    2. Duflos C,
    3. Renard D, et al.
    Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. Arch Neurol. 2012;69(7):847-855.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Kastrup O,
    2. Nes J,
    3. Gasser T,
    4. Keyvani K
    . Three cases of CLIPPERS: a serial clinical, laboratory and MRI follow-up study. J Neurol. 2011;258(12):2140-2146.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Dudesek A,
    2. Rimmele F,
    3. Tesar S, et al.
    CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders. Clin Exp Immunol. 2014;175(3):385-396.
    OpenUrlPubMed
  5. 5.
    1. Tobin WO,
    2. Guo Y,
    3. Krecke KN, et al
    . Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain. 2017;140(9):2415-2425.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Taieb G,
    2. Mulero P,
    3. Psimaras D, et al.
    CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. J Neurol Neurosurg Psychiatry. 2019;90(9):1027-1038.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Román GC,
    2. Gracia F,
    3. Torres A,
    4. Palacios A,
    5. Gracia K,
    6. Harris D
    . Acute transverse myelitis (ATM):Clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol. 2021;12:653786.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Novi G,
    2. Rossi T,
    3. Pedemonte E, et al.
    Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e797.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Gold DM,
    2. Galetta SL
    . Neuro-ophthalmologic complications of coronavirus disease 2019 (COVID-19). Neurosci Lett. 2021;742:135531.
    OpenUrlPubMed
  10. 10.↵
    1. François J,
    2. Collery AS,
    3. Hayek G, et al.
    Coronavirus disease 2019–associated ocular neuropathy with panuveitis: a case report. JAMA Ophthalmol. 2021;139(2):247-249.
    OpenUrl
  11. 11.↵
    1. Rodríguez-Rodríguez MS,
    2. Romero-Castro RM,
    3. Alvarado-de la Barrera C,
    4. González-Cannata MG,
    5. García-Morales AK,
    6. Ávila-Ríos S
    . Optic neuritis following SARS-CoV-2 infection. J Neurovirol. 2021;27(2):359-363.
    OpenUrl
  12. 12.↵
    1. García-Estrada C,
    2. Gómez-Figueroa E,
    3. Alban L,
    4. Arias-Cárdenas A
    . Optic neuritis after COVID-19 vaccine application Clin Exp Neuroimmunol. 2022;13(2):72-74.
    OpenUrl
  13. 13.↵
    1. Ide T,
    2. Kawanami T,
    3. Eriguchi M,
    4. Hara H
    . SARS-CoV-2-related myelin oligodendrocyte glycoprotein antibody-associated disease: a case report and literature review. Intern Med. 2022;61(8):1253-1258.
    OpenUrl
  14. 14.↵
    1. Nagaratnam SA,
    2. Ferdi AC,
    3. Leaney J,
    4. Lee RLK,
    5. Hwang YT,
    6. Heard R
    . Acute disseminated encephalomyelitis with bilateral optic neuritis following ChAdOx1 COVID-19 vaccination. BMC Neurol. 2022;22(1):54.
    OpenUrl
  15. 15.↵
    1. Siow I,
    2. Lee KS,
    3. Zhang JJY,
    4. Saffari SE,
    5. Ng A
    . Encephalitis as a neurological complication of COVID-19: a systematic review and meta-analysis of incidence, outcomes, and predictors. Eur J Neurol. 2021;28(10):3491-3502.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Netravathi M,
    2. Dhamija K,
    3. Gupta M, et al.
    COVID-19 vaccine associated demyelination & its association with MOG antibody. Mult Scler Relat Disord. 2022;60:103739. doi. 10.1016/j.msard.2022.103739.
    OpenUrlCrossRef
  17. 17.↵
    1. Francis AG,
    2. Elhadd K,
    3. Camera V, et al.
    Acute inflammatory diseases of the central nervous system after SARS-CoV-2 vaccination. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200063. doi: 10.1212/NXI.0000000000200063.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Jarius S,
    2. Bieber N,
    3. Haas J,
    4. Wildemann B
    . MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature. J Neurol. 2022;269(10):5198-5212. doi. 10.1007/s00415-022-11194-9.
    OpenUrlCrossRef
  19. 19.↵
    1. Alvarez LM,
    2. Neo YN,
    3. Davagnanam I, et al.
    Post vaccination optic neuritis: observations from the SARS-CoV-2 pandemic. 2021. Available at SSRN: https://ssrn.com/abstract=3889990 or http://dx.doi.org/10.2139/ssrn.3889990.
  20. 20.↵
    1. Xia H,
    2. Lazartigues E
    . Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem. 2008;107(6):1482-1494.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Ismail II,
    2. Salama S
    . Association of CNS demyelination and COVID-19 infection: an updated systematic review. J Neurol. 2022;269(2):541-576. doi. 10.1007/s00415-021-10752-x.
    OpenUrlCrossRef
  22. 22.↵
    1. Powell AM,
    2. Black MM
    . Epitope spreading: protection from pathogens, but propagation of autoimmunity? Clin Exp Dermatol. 2001;26(5):427-433. doi. 10.1046/j.1365-2230.2001.00852.x.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Velikova T,
    2. Georgiev T
    . SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. 2021;41(3):509-518.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Sriwastava S,
    2. Shrestha AK,
    3. Khalid SH,
    4. Colantonio MA,
    5. Nwafor D,
    6. Srivastava S
    . Spectrum of neuroimaging findings in post-COVID-19 vaccination: a case series and review of literature. Neurol Int. 2021;13(4):622-639.
    OpenUrl

Letters: Rapid online correspondence

  • RE: Relapsing Encephalomyelitis After COVID-19 Infection and Vaccination. Neurology - Neuroimmunology Neuroinflammation (2023); 10(3): e200112
    • Scott Newsome, Neurologist, Johns Hopkins University School of Medicine
    • Shuvro Roy, Neurologist, Johns Hopkins University School of Medicine
    Submitted May 03, 2023
  • Relapsing Encephalomyelitis After COVID-19 Infection and Vaccination
    • Guillaume Taieb, Neurologist, Department of Neurology, MS Unit, CHU Montpellier, Hopital Guy de Chauliac, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 5
    • Xavier Ayrignac, Neurologist, Department of Neurology, MS Unit, CHU Montpellier, Hopital Guy de Chauliac, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 5
    • Clarisse Carra-Dalliere, Neurologist, Department of Neurology, MS Unit, CHU Montpellier, Hopital Guy de Chauliac, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 5
    • Pierre Labauge, Neurologist, Department of Neurology, MS Unit, CHU Montpellier, Hopital Guy de Chauliac, 80 avenue Augustin Fliche, 34295 Montpellier Cedex 5
    • Geneviève de Saint Basile, Geneticist, Centre d’Etude des Déficits Immunitaires, AP-HP, Hôpital Necker-Enfants Malades, F-75015, Paris France
    Submitted April 19, 2023
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Case Presentation
    • Differential Diagnosis
    • Final Diagnosis and Treatment
    • Discussion
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Demyelinating disease (CNS)
  • Autoimmune diseases
  • COVID-19
  • Vasculitis
  • Transverse myelitis

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise